FDA Eyes Adverse Events For Mylan's Wixela Inhub

Assessing Need For Additional Reminders About Differences To Advair

 
• By Derrick Gingery
  
Survelliance camera
The FDA's Office of Generic Drugs does not want differences between complex generics and their reference products to hinder uptake • Source: Shutterstock

More from Regulation

More from Policy & Regulation